Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)

BACKGROUND: Administration of convalescent plasma may serve as an adjunct to supportive treatment to prevent COVID-19 progression and death. We aimed to evaluate the efficacy and safety of 2 volumes of intravenous convalescent plasma (CP) with high antibody titers for the treatment of severe cases o...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Alice T.W., Rocha, Vanderson, Mendrone-Júnior, Alfredo, Calado, Rodrigo T., De Santis, Gil C., Benites, Bruno D., Costa-Lima, Carolina, Vargas, Taiani, Marques, Leonardo S., Fernandes, Juliana C., Breda, Felipe C., Wendel, Silvano, Fachini, Roberta, Rizzo, Luiz V., Kutner, José Mauro, Avelino-Silva, Vivian I., Machado, Rafael R.G., Durigon, Edison L., Chevret, Sylvie, Kallas, Esper G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923059/
https://www.ncbi.nlm.nih.gov/pubmed/35308034
http://dx.doi.org/10.1016/j.lana.2022.100216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923059/
https://www.ncbi.nlm.nih.gov/pubmed/35308034
http://dx.doi.org/10.1016/j.lana.2022.100216

Ejemplares similares